---
layout: default
title: Fluocinolone Acetonide
parent: Model Prediction Only (L5)
nav_order: 718
evidence_level: L5
indication_count: 4
---

# Fluocinolone Acetonide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **4** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Fluocinolone Acetonide: From Topical Corticosteroid Use to Hypertrophic Lichen Planus

## One-Sentence Summary

Fluocinolone acetonide is a topical corticosteroid marketed in the US as oil, cream, ointment, solution and implant products. The TxGNN model predicts it may be effective for **hypertrophic lichen planus**, but this is a **model prediction only**: **0 clinical trials** and **0 publications** directly support it. The record lists no original indication, so it is unclear whether lichen planus is truly a new use.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in the record (class: topical corticosteroid) |
| Predicted New Indication | Hypertrophic lichen planus |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available for this drug. Based on class knowledge, fluocinolone acetonide is a topical corticosteroid. Corticosteroids have anti-inflammatory and immunosuppressive effects, and they are widely used in inflammatory skin diseases.

Lichen planus is a T-cell-mediated lichenoid inflammatory disease, so a corticosteroid is a plausible treatment at the class level. This is not evidence specific to fluocinolone acetonide.

The model also gives three lichen planus variants an identical score of 99.42%: hypertrophic, annular atrophic and pigmentosus. This suggests the model is propagating a parent-disease signal rather than variant-specific evidence. The score should be read with that in mind.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available for hypertrophic lichen planus.

For the lower-ranked prediction **lichen planus pemphigoides** (score 99.34%), the record contains three indirect publications. They studied related corticosteroids (fluocinonide, clobetasol), **not fluocinolone acetonide**, so they support only the class-level rationale:

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [8065723](https://pubmed.ncbi.nlm.nih.gov/8065723/) | 1994 | RCT (double-blind) | Oral Surg Oral Med Oral Pathol | Compared 0.05% clobetasol and 0.05% fluocinonide ointment in orabase for oral vesiculoerosive diseases |
| [6996618](https://pubmed.ncbi.nlm.nih.gov/6996618/) | 1980 | Clinical study | Arch Dermatol | 0.05% fluocinonide in an adhesive base in 89 patients (including lichen planus); 7 of 15 responded completely and 8 partially in the double-blind phase |
| [14620208](https://pubmed.ncbi.nlm.nih.gov/14620208/) | 2003 | Review | Quintessence Int | Desquamative gingivitis as an early sign of mucocutaneous disease |

---

## US Market Information

Approved indication text is empty for all listed authorizations. Main authorizations (5 of 20):

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|-----------|
| ANDA202847 | fluocinolone acetonide | Oil | Bryant Ranch Prepack |
| ANDA210539 | Fluocinolone Acetonide | Oil | Glenmark Pharmaceuticals Inc., USA |
| ANDA090982 | Fluocinolone Acetonide | Oil | A-S Medication Solutions |
| ANDA212760 | Fluocinolone Acetonide | Oil | Quagen Pharmaceuticals LLC |
| ANDA089526 | Fluocinolone Acetonide | Cream | Cosette Pharmaceuticals, Inc. |

Other dosage forms in the record: solution, implant, ointment.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The high TxGNN score (99.42%) is not backed by any trial or publication for hypertrophic lichen planus, and the three lichen planus variants share an identical score. The mechanism rationale rests on corticosteroid class knowledge only, and the safety data is missing.

**To proceed, the following is needed:**
- Package insert warnings and contraindications (blocking for safety screening)
- Mechanism of action data for fluocinolone acetonide
- The drug's original approved indications, to confirm whether lichen planus is a genuinely new use
- A literature and trial search for fluocinolone acetonide itself in lichen planus
- Route compatibility assessment (topical vs. other dosage forms)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

